| Cancer Treatment and Pharmacology | Lifetime | 20 | UG 1 | 99.90 |
| Advanced Breast Cancer Therapies | Lifetime | 9 | UG 1 | 99.84 |
| HER2/EGFR in Cancer Research | Lifetime | 17 | UG 1 | 99.87 |
| Breast Cancer Treatment Studies | Lifetime | 53 | UG 1 | 99.80 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 107 | UG 1 | 99.72 |
| Peptidase Inhibition and Analysis | Lifetime | 104 | UG 1 | 99.48 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 208 | UG 1 | 99.57 |
| Brain Metastases and Treatment | Lifetime | 97 | UG 1 | 99.07 |
| Colorectal Cancer Treatments and Studies | Lifetime | 328 | UG 1 | 98.97 |
| Cancer Genomics and Diagnostics | Lifetime | 601 | UG 1 | 98.89 |
| Cancer Cells and Metastasis | Lifetime | 398 | UG 1 | 98.26 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 222 | UG 1 | 98.04 |
| Lung Cancer Research Studies | Lifetime | 545 | UG 1 | 98.06 |
| Cancer-related Molecular Pathways | Lifetime | 725 | UG 1 | 97.63 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 724 | UG 1 | 96.74 |
| Multiple and Secondary Primary Cancers | Lifetime | 945 | UG 1 | 91.63 |
| PARP inhibition in cancer therapy | Lifetime | 883 | UG 1 | 91.48 |
| Chemotherapy-related skin toxicity | Lifetime | 777 | UG 1 | 82.02 |
| Cancer Treatment and Pharmacology | 2021-2025 | 3 | UG 1 | 99.96 |
| HER2/EGFR in Cancer Research | 2021-2025 | 3 | UG 1 | 99.96 |
| Breast Cancer Treatment Studies | 2021-2025 | 7 | UG 1 | 99.95 |
| Advanced Breast Cancer Therapies | 2021-2025 | 5 | UG 1 | 99.92 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 35 | UG 1 | 99.85 |
| Cancer Cells and Metastasis | 2021-2025 | 26 | UG 1 | 97.96 |
| Cancer-related Molecular Pathways | 2021-2025 | 11 | UG 1 | 98.89 |
| Brain Metastases and Treatment | 2021-2025 | 21 | UG 1 | 99.12 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 49 | UG 1 | 98.70 |
| Cancer Genomics and Diagnostics | 2021-2025 | 124 | UG 1 | 98.98 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 40 | UG 1 | 93.28 |
| Peptidase Inhibition and Analysis | 2021-2025 | 396 | UG 1 | 92.72 |
| Lung Cancer Research Studies | 2021-2025 | 571 | UG 1 | 93.62 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 754 | UG 1 | 92.81 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 683 | UG 1 | 92.01 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 585 | UG 1 | 89.87 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 893 | UG 1 | 87.72 |
| Cancer Diagnosis and Treatment | 2021-2025 | 640 | UG 1 | 78.48 |
| PARP inhibition in cancer therapy | 2021-2025 | 810 | UG 1 | 80.51 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 480 | UG 1 | 76.97 |
| Estrogen and related hormone effects | 2021-2025 | 597 | UG 1 | 77.50 |
| Cancer Risks and Factors | 2021-2025 | 680 | UG 1 | 79.16 |
